Rezolute, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel treatments for rare metabolic and endocrine disorders. Founded in 2017 and headquartered in San Diego, California, Rezolute applies a precision medicine approach to address diseases with limited or no approved therapies. The company’s research leverages advanced molecular biology and antibody engineering to create targeted interventions that modulate key biochemical pathways.
Rezolute’s lead product candidate, RZ358, is an antibody antagonist designed to treat congenital hyperinsulinism, a condition characterized by excessive insulin secretion leading to persistent hypoglycemia. The company is also advancing RZ402, a small molecule therapy aimed at restoring glucose homeostasis in patients with glycogen storage disease type Ia and other related metabolic disorders. Both programs have shown promising preclinical data and are progressing through regulatory interactions and clinical trial preparations.
In addition to its internal development activities, Rezolute collaborates with academic institutions, contract research organizations and patient advocacy groups to accelerate its pipeline. While its primary operations are based in the United States, the company is actively engaging with European regulatory authorities to support potential multinational clinical studies. These partnerships help Rezolute expand its scientific expertise and access patient populations across multiple geographies.
Rezolute’s leadership team comprises seasoned professionals with extensive experience in biopharmaceutical research, clinical development and regulatory affairs. Guided by a board of directors with deep expertise in rare disease drug development, the company is committed to delivering breakthrough therapies that address unmet medical needs. Rezolute continues to build its capabilities in translational research, aiming to advance its pipeline efficiently and responsibly.
AI Generated. May Contain Errors.
